SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue for the March 2023 quarter is pegged at Rs. 7821.60 millions against Rs. 7919.20 millions recorded during the year-ago period.The Total Profit for the quarter ended March 2023 of Rs. 1314.80 millions grew from Rs.-558.70 millionsOperating profit for the quarter ended March 2023 rose to 1947.30 millions as compared to 1923.60 millions of corresponding quarter ended March 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 7821.60 7919.20 -1.23 32163.40 32175.10 -0.04 32163.40 32175.10 -0.04
Other Income 279.70 189.40 47.68 1015.20 762.20 33.19 1015.20 762.20 33.19
PBIDT 1947.30 1923.60 1.23 9009.30 8320.50 8.28 9009.30 8320.50 8.28
Interest 6.50 2.70 140.74 18.10 19.90 -9.05 18.10 19.90 -9.05
PBDT 2044.80 2215.90 -7.72 8981.50 8416.40 6.71 8981.50 8416.40 6.71
Depreciation 171.80 153.50 11.92 657.70 681.90 -3.55 657.70 681.90 -3.55
PBT 1873.00 2062.40 -9.18 8323.80 7734.50 7.62 8323.80 7734.50 7.62
TAX 558.20 2621.10 -78.70 2276.80 3968.70 -42.63 2276.80 3968.70 -42.63
Deferred Tax -7.60 24.70 -130.77 -183.70 -105.00 74.95 -183.70 -105.00 74.95
PAT 1314.80 -558.70 -335.33 6047.00 3765.80 60.58 6047.00 3765.80 60.58
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 24.90 24.29 2.50 28.01 25.86 8.32 28.01 25.86 8.32

Glaxosmithkline Phar Share Price

2451.80 32.70 (1.35%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×